However, this hydroxylation is inhibited during hypoxia, resulting in HIF-1α accumulation and vascular remodeling.409 Thus, it has been demonstrated that Egl-9 family hypoxia-inducible factor 1 (EGLN1) mutation decreases the hypoxic response of CCHD via the PHD2/HIF-1 pathway, which might be a viable target for CCHD therapy.410 Liu et al. discovered that Cited2 functional loss causes abnormalities in the heart and neural tube development, partially due to the regulation of HIF-1α transcriptional activity in the absence of Cited2,411 emphasizing its significant role in the development of CHD. Here, EGLN1 is linked to coronary artery disorder.